DE69429657D1 - Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten - Google Patents
Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheitenInfo
- Publication number
- DE69429657D1 DE69429657D1 DE69429657T DE69429657T DE69429657D1 DE 69429657 D1 DE69429657 D1 DE 69429657D1 DE 69429657 T DE69429657 T DE 69429657T DE 69429657 T DE69429657 T DE 69429657T DE 69429657 D1 DE69429657 D1 DE 69429657D1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- viral diseases
- modified
- cancer
- treating cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 241000282465 Canis Species 0.000 abstract 1
- 241000219122 Cucurbita Species 0.000 abstract 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 abstract 1
- 208000004729 Feline Leukemia Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000007660 Residual Neoplasm Diseases 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000010926 purge Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0093—Purging against cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6318893A | 1993-05-14 | 1993-05-14 | |
PCT/US1994/005374 WO1994026284A1 (en) | 1993-05-14 | 1994-05-12 | Use of modified tall-104 cells to treat cancer and viral diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69429657D1 true DE69429657D1 (de) | 2002-02-21 |
DE69429657T2 DE69429657T2 (de) | 2002-09-12 |
Family
ID=22047549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69429657T Expired - Fee Related DE69429657T2 (de) | 1993-05-14 | 1994-05-12 | Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0697875B1 (de) |
JP (1) | JP3541950B2 (de) |
AT (1) | ATE211915T1 (de) |
AU (1) | AU694430B2 (de) |
CA (1) | CA2162732C (de) |
DE (1) | DE69429657T2 (de) |
DK (1) | DK0697875T3 (de) |
ES (1) | ES2171169T3 (de) |
PT (1) | PT697875E (de) |
WO (1) | WO1994026284A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022538A (en) * | 1995-06-06 | 2000-02-08 | The Wistar Institute Of Anatomy And Biology | Method of treating malignancies |
US5800539A (en) * | 1995-11-08 | 1998-09-01 | Emory University | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease |
US6213127B1 (en) | 1996-07-29 | 2001-04-10 | Emory University | Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity |
AU7267398A (en) | 1997-04-30 | 1998-11-24 | Hans Klingemann | Natural killer cell lines and methods of use |
US6828147B1 (en) | 1999-02-24 | 2004-12-07 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
AU3373300A (en) * | 1999-02-24 | 2000-09-14 | Wistar Institute Of Anatomy And Biology, The | Method of modifying cytotoxic cells and uses thereof |
CA2437980A1 (en) * | 2001-02-16 | 2002-08-29 | The Wistar Institute Of Anatomy And Biology | Methods of treating inflammation, particularly diabetes |
ITMI20022118A1 (it) * | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo. |
-
1994
- 1994-05-12 AT AT94917384T patent/ATE211915T1/de not_active IP Right Cessation
- 1994-05-12 JP JP52573694A patent/JP3541950B2/ja not_active Expired - Fee Related
- 1994-05-12 AU AU69126/94A patent/AU694430B2/en not_active Ceased
- 1994-05-12 DE DE69429657T patent/DE69429657T2/de not_active Expired - Fee Related
- 1994-05-12 DK DK94917384T patent/DK0697875T3/da active
- 1994-05-12 PT PT94917384T patent/PT697875E/pt unknown
- 1994-05-12 ES ES94917384T patent/ES2171169T3/es not_active Expired - Lifetime
- 1994-05-12 WO PCT/US1994/005374 patent/WO1994026284A1/en active IP Right Grant
- 1994-05-12 EP EP94917384A patent/EP0697875B1/de not_active Expired - Lifetime
- 1994-05-12 CA CA002162732A patent/CA2162732C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3541950B2 (ja) | 2004-07-14 |
CA2162732C (en) | 2007-01-09 |
DK0697875T3 (da) | 2002-04-29 |
AU694430B2 (en) | 1998-07-23 |
JPH08510131A (ja) | 1996-10-29 |
CA2162732A1 (en) | 1994-11-24 |
ES2171169T3 (es) | 2002-09-01 |
AU6912694A (en) | 1994-12-12 |
DE69429657T2 (de) | 2002-09-12 |
ATE211915T1 (de) | 2002-02-15 |
PT697875E (pt) | 2002-07-31 |
EP0697875A1 (de) | 1996-02-28 |
EP0697875B1 (de) | 2002-01-16 |
EP0697875A4 (de) | 1997-06-04 |
WO1994026284A1 (en) | 1994-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE394110T1 (de) | Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems | |
CY1121447T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης | |
Li et al. | Mesenchymal stem cells: characteristics, function, and application | |
ATE298371T1 (de) | Nicht-primaten lentivirale vektoren und verpackungssysteme | |
IL197686A0 (en) | Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith | |
MY121548A (en) | Compounds and methods for the treatment of cancer | |
HK1028935A1 (en) | Treatment of neoplasms with interferon-sernsitive,clonal viruses | |
BR9814857A (pt) | Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril | |
TNSN06059A1 (en) | Use of polypeptides of the cupredoxin family in cancer therapy | |
DE69429657D1 (de) | Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten | |
Kamensek et al. | Irradiation, cisplatin, and 5-azacytidine upregulate cytomegalovirus promoter in tumors and muscles: implementation of non-invasive fluorescence imaging | |
DE69839875D1 (de) | Zusammensetzung enthaltend auf festen Teilchen immobilisierte Radioisotopen, sowie deren Verwendung in der Brachytherapie | |
DE3376295D1 (en) | Pharmaceutical composition containing adenosine derivatives for use in treating tumours | |
ATE427746T1 (de) | 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren | |
DK0841912T3 (da) | 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning | |
DE69725882D1 (de) | Adenovirus e4 proteine für induktion von zelltod | |
HUT64569A (en) | A process for preparing polypeptide-type compounds usefules for medical treatment of the human body | |
DE69934987D1 (de) | Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen | |
Rofstad et al. | Radiation and heat sensitivity of cells from two slowly growing human melanoma xenografts | |
ES2366469T3 (es) | Citoprotección por fosfotirosina. | |
Lambreva et al. | Synergistic electrochemotherapy on cancer cells by photodynamically active cytostatic agents | |
Fleenor | Contrasting Roles of C/EBPα and Notch in Ionizing Radiation-induced Multipotent Hematopoietic Progenitor Cell Self-renewal Defects | |
Shou et al. | 454. Mouse Models for the Analysis of Genetic Risk Factors for Hematopoietic Transformation in XSCID Gene Therapy | |
DE19780958D2 (de) | Verwendung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung | |
Chevillard et al. | Stimulating effect of misonidazole on growth of A549 cells maintained in organotypic and monolayer culture conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |